Author Response to Letter to the Editor: Evaluation of Clemastine Effects on Clinical and Electrodiagnostic Parameters in Carpal Tunnel Syndrome (CTS) Patients: A Preliminary Placebo-Controlled Double Blind RCT
Gholamreza Raissi, Tannaz Ahadi, Kamyar Kazemi, Seyed Pezhman Madani, Simin Sajadi, Hosna Soleymanzadeh, Negar Kariznoee · 2026
Read Author Response to Letter to the Editor: Evaluation of Clemastine Effects on Clinical and Electrodiagnostic Parameters in Carpal Tunnel Syndrome (CTS) Patients: A Preliminary Placebo-Controlled Double Blind RCT by Gholamreza Raissi, Tannaz Ahadi, Kamyar Kazemi, Seyed Pezhman Madani, Simin Sajadi, Hosna Soleymanzadeh, Negar Kariznoee (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13591084.txt.
Description
Scholars who ran a small trial of the allergy drug clemastine for carpal tunnel syndrome reply here to a critical letter about their work. Gholamreza Raissi and six co-authors wrote the response in 2026, defending their numbers point by point.
One dispute concerned the sex balance of the two trial groups. The authors state that their table is exact: five men and seven women on the drug, against two men and ten women on placebo. That gap is too small to reach significance, and they ask the critics to name the claimed discrepancy. They also address the stricter significance threshold the letter proposed. The exchange shows how preliminary trials get stress-tested in public after publication.
Catalog record
| CREATOR | Gholamreza Raissi, Tannaz Ahadi, Kamyar Kazemi, Seyed Pezhman Madani, Simin Sajadi, Hosna Soleymanzadeh, Negar Kariznoee |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 5 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |